Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650455 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 489
- Enrollment target
NCT00650455 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 489 participants.
The verdict
NCT00650455, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 489 participants
- Enrollment target
Study Summary
The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy of valdecoxib 10 mg QD versus naproxen 500 mg BID, in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe Rheumatoid Arthritis population.
Interventions
- DRUG placebo
- DRUG valdecoxib
- DRUG naproxen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650455
The ClinicalTrials.gov registry entry for NCT00650455 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 489 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00650455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650455 about?
NCT00650455 is a clinical study titled "Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients". The objectives of the study were to evaluate the efficacy, safety, and tolerability of valdecoxib 10 mg once daily (QD) or naproxen 500 mg twice daily (BID) versus placebo, and to assess the efficacy of valdecoxib 10 mg QD versus naproxen 500 mg BID, in treating the signs and symptoms of rheumatoid ...
What is the current status of trial NCT00650455?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 489 participants. The study started on 2003-02. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00650455?
The interventions under investigation include: placebo (DRUG), valdecoxib (DRUG), naproxen (DRUG).
Who is sponsoring clinical trial NCT00650455?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.